The interpretation of non-coding variants still constitutes a major challenge in the application of whole-genome sequencing in Mendelian disease, especially for single-nucleotide and other small non-coding variants. Here we present Genomiser, an analysis framework that is able not only to score the relevance of variation in the non-coding genome, but also to associate regulatory variants to specific Mendelian diseases. Genomiser scores variants through either existing methods such as CADD or a bespoke machine learning method and combines these with allele frequency, regulatory sequences, chromosomal topological domains, and phenotypic relevance to\ua0discover variants associated to specific Mendelian disorders. Overall, Genomiser is able to...
Background: Whole exome sequencing studies identify hundreds to thousands of rare protein coding var...
Across a variety of Mendelian disorders, similar to 50-75% of patients do not receive a genetic diag...
Across a variety of Mendelian disorders, similar to 50-75% of patients do not receive a genetic diag...
The interpretation of non-coding variants still constitutes a major challenge in the application of ...
Background Whole exome sequencing studies identify hundreds to thousands of rare protein coding v...
Background Whole exome sequencing studies identify hundreds to thousands of rare protein coding v...
Background Whole exome sequencing studies identify hundreds to thousands of rare protein coding v...
Background Whole exome sequencing studies identify hundreds to thousands of rare protein coding v...
Many sequencing studies are now underway to identify the genetic causes for both Mendelian and compl...
The vast majority of the human genome (~98%) is non-coding. A symphony of non-coding sequences resi...
The vast majority of the human genome (~98%) is non-coding. A symphony of non-coding sequences resi...
New sequencing technology has enabled the identification of thousands of single nucleotide polymorph...
Across a variety of Mendelian disorders, similar to 50-75% of patients do not receive a genetic diag...
Across a variety of Mendelian disorders, similar to 50-75% of patients do not receive a genetic diag...
Across a variety of Mendelian disorders, similar to 50-75% of patients do not receive a genetic diag...
Background: Whole exome sequencing studies identify hundreds to thousands of rare protein coding var...
Across a variety of Mendelian disorders, similar to 50-75% of patients do not receive a genetic diag...
Across a variety of Mendelian disorders, similar to 50-75% of patients do not receive a genetic diag...
The interpretation of non-coding variants still constitutes a major challenge in the application of ...
Background Whole exome sequencing studies identify hundreds to thousands of rare protein coding v...
Background Whole exome sequencing studies identify hundreds to thousands of rare protein coding v...
Background Whole exome sequencing studies identify hundreds to thousands of rare protein coding v...
Background Whole exome sequencing studies identify hundreds to thousands of rare protein coding v...
Many sequencing studies are now underway to identify the genetic causes for both Mendelian and compl...
The vast majority of the human genome (~98%) is non-coding. A symphony of non-coding sequences resi...
The vast majority of the human genome (~98%) is non-coding. A symphony of non-coding sequences resi...
New sequencing technology has enabled the identification of thousands of single nucleotide polymorph...
Across a variety of Mendelian disorders, similar to 50-75% of patients do not receive a genetic diag...
Across a variety of Mendelian disorders, similar to 50-75% of patients do not receive a genetic diag...
Across a variety of Mendelian disorders, similar to 50-75% of patients do not receive a genetic diag...
Background: Whole exome sequencing studies identify hundreds to thousands of rare protein coding var...
Across a variety of Mendelian disorders, similar to 50-75% of patients do not receive a genetic diag...
Across a variety of Mendelian disorders, similar to 50-75% of patients do not receive a genetic diag...